Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953960 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Phase 1 study of Multiple Myeloma, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06953960 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 130 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06953960, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be a dose escalation phase where participants will receive various doses of ABBV-453 in combination with daratumumab + dexamethasone, to determine the best dose of ABBV-453. This will be followed by a dose expansion and selection phase where participants will receive 1 of 2 doses of ABBV-453 in combination with daratumumab + dexamethasone, or daratumumab + dexamethasone + pomalidomide (only during the expansion phase). In Substudy 2, there will be a dose escalation phase where participants will receive various doses of ABBV-453 alone. Approximately 130 adult participants with R/R MM will be enrolled in the study in approximately 40 sites worldwide. In Substudy 1 escalation phase, participants will receive oral ABBV-453 tablets in combination with subcutaneous (SC) daratumumab injections + oral dexamethasone tablets and in the expansion phase, will receive oral ABBV-453 tablets in combination with SC daratumumab injections + oral dexamethasone tablets or daratumumab injections + oral pomalidomide + oral dexamethasone tablets. In Substudy 2, Japanese participants will receive oral ABBV-453 tablets. The total study duration is approximately 4.5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution. The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG ABBV-453
- DRUG Pomalidomide
Study Locations (20)
Other
- CHU de Liege /ID# 271430 - Liège
- Rambam Health Care Campus- Haifa /ID# 271256 - Haifa
- Hadassah Medical Center-Hebrew University /ID# 271253 - Jerusalem
New South Wales
- Liverpool Hospital /ID# 272002 - Liverpool
- Calvary Mater Newcastle /ID# 272498 - Waratah
Victoria
- St Vincent's Hospital - Melbourne /ID# 271997 - Fitzroy
- Epworth Hospital /ID# 272497 - Richmond
Tel Aviv
- The Chaim Sheba Medical Center /ID# 271251 - Ramat Gan
- Tel Aviv Sourasky Medical Center /ID# 271252 - Tel Aviv
California
- University of Southern California /ID# 272414 - Los Angeles
Michigan
- University of Michigan Health System - Ann Arbor /ID# 271536 - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214 - New York
North Carolina
- University of North Carolina at Chapel Hill /ID# 272454 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953960
The ClinicalTrials.gov registry entry for NCT06953960 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (76% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT06953960 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, New South Wales, Victoria.
Frequently Asked Questions
What is clinical trial NCT06953960 about?
NCT06953960 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)". Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in dis...
What is the current status of trial NCT06953960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2025-07-23. Estimated completion is 2030-12.
What conditions does trial NCT06953960 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06953960?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), ABBV-453 (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT06953960?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06953960 being conducted?
This trial has 20 study locations across California, Michigan, New York, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.